Fujifilm and Kyowa Hakko Kirin joint venture for biosimilars

March 30, 2012 7:27 AM

Fujifilm Corporation and Kyowa Hakko Kirin Co., Ltd. commenced business operations of the “Fujifilm Kyowa Kirin Biologics Co., Ltd.”, a joint-venture for the development, manufacturing and sales of biosimilars.

Fujifilm Kyowa Kirin Biologics will merge Fujifilm’s advanced production technology, quality control technology and analysis technology developed through its photographic film business over many years, with Kyowa Hakko Kirin’s proprietary technologies and know-how, accumulated through its biopharmaceutical R&D and manufacturing, in order to create revolutionary production processes and to achieve cost reduction for biosimilars. The development and timely introduction of highly reliable, high-quality and cost-competitive biosimilars through this partnership will aim to obtain position as the market leader.

Fujifilm Kyowa Kirin Biologics will first focus on the development of the biosimilar of the fully human anti-TNF-? monoclonal antibody “adalimumab“, a drug with high therapeutic effects for rheumatoid arthritis. After introducing the producing cell already produced by Kyowa Hakko Kirin, Fujifilm Kyowa Kirin Biologics plans to start clinical trials in the beginning of 2013.

The company will then proceed with its development aiming for market introduction 4 to 5 years after the start of clinical trials. It also plans to start clinical trials of  one biosimilar every year after 2014.

Fujifilm Kyowa Kirin Biologics also intends to hold talks with other companies for sales collaboration of biosimilars.

 

Source: Kyowa Hakko Kirin press release


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!